Literature DB >> 32621646

In Vivo Molecular Signatures of Cerebellar Pathology in Spinocerebellar Ataxia Type 3.

Maria do Carmo Costa1, Maria Radzwion1, Hayley S McLoughlin1, Naila S Ashraf1, Svetlana Fischer1, Vikram G Shakkottai1,2, Patrícia Maciel3, Henry L Paulson1, Gülin Öz4.   

Abstract

BACKGROUND: No treatment exists for the most common dominantly inherited ataxia Machado-Joseph disease, or spinocerebellar ataxia type 3 (SCA3). Successful evaluation of candidate therapeutics will be facilitated by validated noninvasive biomarkers of disease pathology recapitulated by animal models.
OBJECTIVE: We sought to identify shared in vivo neurochemical signatures in two mouse models of SCA3 that reflect the human disease pathology.
METHODS: Cerebellar neurochemical concentrations in homozygous YACMJD84.2 (Q84/Q84) and hemizygous CMVMJD135 (Q135) mice were measured by in vivo magnetic resonance spectroscopy at 9.4 tesla. To validate the neurochemical biomarkers, levels of neurofilament medium (NFL; indicator of neuroaxonal integrity) and myelin basic protein (MBP; indicator of myelination) were measured in cerebellar lysates from a subset of mice and patients with SCA3. Finally, NFL and MBP levels were measured in the cerebellar extracts of Q84/Q84 mice upon silencing of the mutant ATXN3 gene.
RESULTS: Both Q84/Q84 and Q135 mice displayed lower N-acetylaspartate than wild-type littermates, indicating neuroaxonal loss/dysfunction, and lower myo-inositol and total choline, indicating disturbances in phospholipid membrane metabolism and demyelination. Cerebellar NFL and MBP levels were accordingly lower in both models as well as in the cerebellar cortex of patients with SCA3 than controls. Importantly, N-acetylaspartate and total choline correlated with NFL and MPB, respectively, in Q135 mice. Long-term sustained RNA interference (RNAi)-mediated reduction of ATXN3 levels increased NFL and MBP in Q84/Q84 cerebella.
CONCLUSIONS: N-acetylaspartate, myo-inositol, and total choline levels in the cerebellum are candidate biomarkers of neuroaxonal and oligodendrocyte pathology in SCA3, aspects of pathology that are reversible by RNAi therapy.
© 2020 International Parkinson and Movement Disorder Society. © 2020 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Machado-Joseph disease; ataxin-3; demyelination; magnetic resonance spectroscopy; polyglutamine

Mesh:

Substances:

Year:  2020        PMID: 32621646      PMCID: PMC7572607          DOI: 10.1002/mds.28140

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  70 in total

Review 1.  Neurospectroscopy: the past, present and future.

Authors:  Carolyn E Mountford; Peter Stanwell; Alexander Lin; Saadallah Ramadan; Brian Ross
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 2.  Repeat expansion disease: progress and puzzles in disease pathogenesis.

Authors:  Albert R La Spada; J Paul Taylor
Journal:  Nat Rev Genet       Date:  2010-04       Impact factor: 53.242

3.  RARE imaging: a fast imaging method for clinical MR.

Authors:  J Hennig; A Nauerth; H Friedburg
Journal:  Magn Reson Med       Date:  1986-12       Impact factor: 4.668

4.  Neurochemical abnormalities in premanifest and early spinocerebellar ataxias.

Authors:  James M Joers; Dinesh K Deelchand; Tianmeng Lyu; Uzay E Emir; Diane Hutter; Christopher M Gomez; Khalaf O Bushara; Lynn E Eberly; Gülin Öz
Journal:  Ann Neurol       Date:  2018-04-10       Impact factor: 10.422

5.  CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1.

Authors:  Y Kawaguchi; T Okamoto; M Taniwaki; M Aizawa; M Inoue; S Katayama; H Kawakami; S Nakamura; M Nishimura; I Akiguchi
Journal:  Nat Genet       Date:  1994-11       Impact factor: 38.330

6.  Axonal dysfunction in the deep white matter in Machado-Joseph disease.

Authors:  Anelyssa D'Abreu; Marcondes França; Simone Appenzeller; Iscia Lopes-Cendes; Fernando Cendes
Journal:  J Neuroimaging       Date:  2008-05-08       Impact factor: 2.486

Review 7.  Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance.

Authors:  Stephen K Fisher; James E Novak; Bernard W Agranoff
Journal:  J Neurochem       Date:  2002-08       Impact factor: 5.372

8.  Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease.

Authors:  Anabela Silva-Fernandes; Sara Duarte-Silva; Andreia Neves-Carvalho; Marina Amorim; Carina Soares-Cunha; Pedro Oliveira; Kenneth Thirstrup; Andreia Teixeira-Castro; Patrícia Maciel
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

9.  Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles.

Authors:  Jillian Friedrich; Holly B Kordasiewicz; Brennon O'Callaghan; Hillary P Handler; Carmen Wagener; Lisa Duvick; Eric E Swayze; Orion Rainwater; Bente Hofstra; Michael Benneyworth; Tessa Nichols-Meade; Praseuth Yang; Zhao Chen; Judit Perez Ortiz; H Brent Clark; Gülin Öz; Sarah Larson; Huda Y Zoghbi; Christine Henzler; Harry T Orr
Journal:  JCI Insight       Date:  2018-11-02

10.  Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.

Authors:  Clévio Nóbrega; Isabel Nascimento-Ferreira; Isabel Onofre; David Albuquerque; Hirokazu Hirai; Nicole Déglon; Luís Pereira de Almeida
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240

View more
  7 in total

1.  Brain structural abnormalities in the preclinical stage of Machado-Joseph disease/spinocerebellar ataxia type 3 (MJD/SCA3): evaluation by MRI morphometry, diffusion tensor imaging and neurite orientation dispersion and density imaging.

Authors:  Mengcheng Li; Xinyuan Chen; Hao-Ling Xu; Ziqiang Huang; Naping Chen; Yuqing Tu; Shirui Gan; Jianping Hu
Journal:  J Neurol       Date:  2021-11-16       Impact factor: 6.682

2.  Impaired Oligodendrocyte Maturation Is an Early Feature in SCA3 Disease Pathogenesis.

Authors:  Kristen H Schuster; Annie J Zalon; Hongjiu Zhang; Danielle M DiFranco; Nicholas R Stec; Zaid Haque; Kate G Blumenstein; Amanda M Pierce; Yuanfang Guan; Henry L Paulson; Hayley S McLoughlin
Journal:  J Neurosci       Date:  2022-01-18       Impact factor: 6.709

3.  A Novel SCA3 Knock-in Mouse Model Mimics the Human SCA3 Disease Phenotype Including Neuropathological, Behavioral, and Transcriptional Abnormalities Especially in Oligodendrocytes.

Authors:  Eva Haas; Rana D Incebacak; Thomas Hentrich; Chrisovalantou Huridou; Thorsten Schmidt; Nicolas Casadei; Yacine Maringer; Carola Bahl; Frank Zimmermann; James D Mills; Eleonora Aronica; Olaf Riess; Julia M Schulze-Hentrich; Jeannette Hübener-Schmid
Journal:  Mol Neurobiol       Date:  2021-10-30       Impact factor: 5.682

4.  Cerebellar morphometric and spectroscopic biomarkers for Machado-Joseph Disease.

Authors:  Catarina Oliveira Miranda; Rui Jorge Nobre; Miguel Castelo-Branco; Luís Pereira de Almeida; Vitor Hugo Paiva; João Valente Duarte; João Castelhano; Lorena Itatí Petrella; José Sereno; Magda Santana; Sónia Afonso; Cristina Januário
Journal:  Acta Neuropathol Commun       Date:  2022-03-19       Impact factor: 7.801

5.  Plasma PolyQ-ATXN3 Levels Associate With Cerebellar Degeneration and Behavioral Abnormalities in a New AAV-Based SCA3 Mouse Model.

Authors:  Karen Jansen-West; Tiffany W Todd; Lillian M Daughrity; Mei Yue; Jimei Tong; Yari Carlomagno; Giulia Del Rosso; Aishe Kurti; Caroline Y Jones; Judith A Dunmore; Monica Castanedes-Casey; Dennis W Dickson; Zbigniew K Wszolek; John D Fryer; Leonard Petrucelli; Mercedes Prudencio
Journal:  Front Cell Dev Biol       Date:  2022-03-21

6.  Pathogenetic Mechanisms Underlying Spinocerebellar Ataxia Type 3 Are Altered in Primary Oligodendrocyte Culture.

Authors:  Kristen H Schuster; Alexandra F Putka; Hayley S McLoughlin
Journal:  Cells       Date:  2022-08-22       Impact factor: 7.666

7.  Antisense Oligonucleotide Therapy Targeted Against ATXN3 Improves Potassium Channel-Mediated Purkinje Neuron Dysfunction in Spinocerebellar Ataxia Type 3.

Authors:  David D Bushart; Annie J Zalon; Hongjiu Zhang; Logan M Morrison; Yuanfang Guan; Henry L Paulson; Vikram G Shakkottai; Hayley S McLoughlin
Journal:  Cerebellum       Date:  2021-02       Impact factor: 3.847

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.